Aquiluna Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 77.69%
- Profit Growth 55.11%
- Ebitda 4528.34%
- Net Worth -5.69%
- Total Assets 143.13%
About Aquiluna Pharmaceuticals
Aquiluna Pharmaceuticals Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 November 2019 (Five years and two months 28 days old ). Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Alpana Tripathi and Chetan Shukla serve as directors at the Company.
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299UP2019PTC123790
- Company No.
123790
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Nov 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Aquiluna Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alpana Tripathi  | Director | 25-Nov-2019 | Current |
| Chetan Shukla | Director | 25-Nov-2019 | Current |
Financial Performance of Aquiluna Pharmaceuticals.
Aquiluna Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 77.69% increase. The company also saw a substantial improvement in profitability, with a 55.11% increase in profit. The company's net worth dipped by a decrease of 5.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aquiluna Pharmaceuticals?
Unlock access to Aquiluna Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aquiluna Pharmaceuticals?
Unlock and access historical data on people associated with Aquiluna Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aquiluna Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aquiluna Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.